When we stratified and compared the estimated risk of GRSs calculated from the three novel and 21 replicated (after exclusion of three markers on FGFR2/TOX3/ESR1 among 24 replicated variants) “Asian-specific BRCAX” markers according to “shared between population” (FGFR2/TOX3/ESR1) genotype status, those with multiple risk alleles of FGFR2/TOX3/ESR1 showed steeper increases in risk for breast cancers, compared with those in none or one allele groups (Fig. 2C). The gene discussed is FGFR2; the disease is breast carcinoma.